208 related articles for article (PubMed ID: 33350679)
1. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
Desage AL; Bouleftour W; Rivoirard R; Magne N; Collard O; Fournel P; Tissot C
Am J Clin Oncol; 2021 Mar; 44(3):109-113. PubMed ID: 33350679
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
3. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
4. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study.
Nakashima K; Homma Y; Taniguchi J; Kubota N; Otsuki A; Ito H; Otsuka Y; Kondo K; Ohfuji S; Fukushima W; Hirota Y
J Infect Chemother; 2023 Nov; 29(11):1038-1045. PubMed ID: 37481070
[TBL] [Abstract][Full Text] [Related]
6. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
[TBL] [Abstract][Full Text] [Related]
7. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
8. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
10. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
11. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
12. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
13. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Immunotherapy; 2020 Nov; 12(16):1183-1193. PubMed ID: 32878511
[No Abstract] [Full Text] [Related]
14. Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy.
Nigro O; Ferrari A; Casanova M; Orbach D; Leruste A; Gatz SA; Frappaz D; Massimino M
Tumori; 2021 Aug; 107(4):276-281. PubMed ID: 33877022
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Keam B; Kang CK; Jun KI; Moon SM; Suh KJ; Lee DW; Ock CY; Kim M; Choi Y; Lim Y; Lee KH; Kim SH; Kim TM; Kim TY; Oh DY; Kim DW; Im SA; Lee JS; Kim ES; Kim HB; Kim NJ; Kim YJ; Park WB; Oh MD
Clin Infect Dis; 2020 Jul; 71(2):422-425. PubMed ID: 31680143
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
18. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
19. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
20. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]